SCHEMBL4970014

SCHEMBL4970014

Nc1ccccc1OC=COc1ccccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
TDP1 Q9NUW8 2/20 0.54
ADRA2B P18089 1/20 0.54
PTGS1 P23219 1/20 0.54
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
ALOX15 P16050 3/20 0.45
CYP3A4 P08684 2/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 4/20 0.42
RCE1 Q9Y256 1/20 0.42
APP P05067 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11454919 0.86 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL21011872 0.86 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL18666445 0.86 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL28152556 0.83 MAOB (0.43) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL25728659 0.81 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL7470893 0.80 ALDH1A1 (0.56) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL2624880 0.80 ALDH1A1 (0.50) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL12168441 0.80 ALDH1A1 (0.50) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL10423431 0.75 ALDH1A1 (0.45) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL19957491 0.75 ALDH1A1 (0.50) ALDH1A1TDP1ADRA2BPTGS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719486-A1 CONJUGATES AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP claimed
EP-4719498-A1 RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF Full-Life Technologies UK Limited (GB) 2026-04-08 EP claimed
WO-2025199636-A1 TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF MCMASTER UNIVERSITY (CA) 2025-10-02 WO claimed
EP-4619411-A1 DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF Full-Life Technologies HK Limited (HK) 2025-09-24 EP claimed
WO-2024245407-A1 CONJUGATES AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-12-05 WO claimed
WO-2024245421-A1 RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-12-05 WO claimed
WO-2024157264-A9 PLANT HEALTH / PLANT VIGOR IMPROVING MIXTURE OF INSECTICIDES ADAMA MAKHTESHIM LTD. (IL) 2024-10-24 WO claimed
WO-2024157264-A1 PLANT HEALTH / PLANT VIGOR IMPROVING MIXTURE OF INSECTICIDES ADAMA MAKHTESHIM LTD. (IL) 2024-08-02 WO claimed
WO-2024083224-A1 DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF RELATED APPLICATIONS FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-04-25 WO claimed
WO-2022132487-A1 BREAST CANCER POST-TREATMENT SUPPORT GARMENT JNG INTERNATIONAL LLC (US) 2022-06-23 WO claimed
CN-114522157-A Application of calcium ion chelating agent in preparation of preparation for improving phagocytic capacity of vascular endothelial cells 重庆大学 2022-05-24 CN claimed
CN-114302761-A Methods and compositions for reversing platelet aggregation 特鲁维安科学公司 2022-04-08 CN claimed
US-10233508-B2 Virus particle stabilisation and method for isolating viral nucleic acids QIAGEN GMBH (DE) 2019-03-19 US claimed
US-20180074055-A1 METHOD FOR THE QUANTIFICATION OF PARASITE EGGS IN FECES Parasight System Inc. 2018-03-15 US claimed
EP-1497276-B1 CONVERSION OF TAXANE MOLECULES NATURAL PHARMACEUTICALS INC (US) 2008-08-20 EP claimed
US-5679564-A CULTURING IN A MEDIUM WITH BILE, BILE ACID OR ITS SALTS AND A DIVALENT CATION CHELATOR; HEATING IN AIR OR A GAS MIXTURE ANTEX BIOLOGICS, INC. (US) 1997-10-21 US claimed
US-12612614-B2 Stabilization of RNA QIAGEN GMBH (DE) 2026-04-28 US disclosed
US-20260097224-A1 METHODS FOR MODULATING NEUROPLASTICITY AMPA INC (US) 2026-04-09 US disclosed
CN-101620225-A Subcellular area targeting, long-wavelength and dual-wavelength ratio method Ca<2+> fluorescent probe and synthesis method thereof BEIJING INST TECHNOLOGY 2010-01-06 CN disclosed
US-20040009919-A1 Protein kinase C peptides for use in withdrawal NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612614-B2 Stabilization of RNA NSUN3, NSUN2, NOP2 ALDH1A1 3687/4885TDP1 1284/4885ADRA2B 4260/4885
US-20260097224-A1 METHODS FOR MODULATING NEUROPLASTICITY GABRE, BDNF, GRIN2A ALDH1A1 3210/4885TDP1 2382/4885ADRA2B 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.